Gene expression data from CD34+ BMMCs/PBMCs from JAK2V617F positive MPN patients vs. Healthy controls. Gene expression data from CD34+ BMMCs/PBMCs from JAK2V617F positive MPN patients vs. Healthy controls

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET) and seconday myelofibrosis (pPV-MF or pET-MF) In this dataset, we compare the gene expression data of bone marrow (BM) or peripheral blood (PB) mononuclear cells of CD34+ cells from JAK2V617F mutated patients vs. healthy donors Overall design: 19 JAK2V617F MPN patients and 6 healthy controls were analyzed

费城染色体阴性骨髓增殖性肿瘤（Philadelphia chromosome-negative myeloproliferative neoplasms, MPN）涵盖原发性骨髓纤维化（primary myelofibrosis, PMF）、真性红细胞增多症（polycythemia vera, PV）、原发性血小板增多症（essential thrombocythemia, ET）以及继发性骨髓纤维化（secondary myelofibrosis，即pPV-MF或pET-MF）。本数据集对比了JAK2V617F突变患者来源的CD34+细胞的骨髓（bone marrow, BM）或外周血（peripheral blood, PB）单个核细胞的基因表达数据与健康供体的对应数据。实验设计：共纳入19例JAK2V617F突变的MPN患者与6例健康对照进行分析。